Abstract

Many genes are differentially expressed in the cortex of people with schizophrenia, implicating factors that control transcription more generally. Hormone nuclear receptors dimerize to coordinate context-dependent changes in gene expression. We hypothesized that members of two families of nuclear receptors (NR4As), and retinoid receptors (RARs and RXRs), are altered in the dorsal lateral prefrontal cortex (DLPFC) of people with schizophrenia. We used next generation sequencing and then qPCR analysis to test for changes in mRNA levels for transcripts encoding nuclear receptors: orphan nuclear receptors (3 in the NR4A, 3 in the RAR, 3 in the RXR families and KLF4) in total RNA extracted from the DLPFC from people with schizophrenia compared to controls (n = 74). We also correlated mRNA levels with demographic factors and with estimates of antipsychotic drug exposure (schizophrenia group only). We tested for correlations between levels of transcription factor family members and levels of genes putatively regulated by these transcription factors. We found significantly down regulated expression of NR4A1 (Nurr 77) and KLF4 mRNAs in people with schizophrenia compared to controls, by both NGS and qPCR (p = or <0.01). We also detected decreases in NR4A2 (Nurr1) and RXRB mRNAs by using qPCR in the larger cohort (p<0.05 and p<0.01, respectively). We detected decreased expression of RARG and NR4A2 mRNAs in females with schizophrenia (p<0.05). The mRNA levels of NR4A1, NR4A2 and NR4A3 were all negative correlated with lifetime estimates of antipsychotic exposure. These novel findings, which may be influenced by antipsychotic drug exposure, implicate the orphan and retinoid nuclear receptors in the cortical pathology found in schizophrenia. Genes down stream of these receptors can be dysregulated as well, but the direction of change is not immediately predictable based on the putative transcription factor changes.
Introduction

Schizophrenia is a serious psychiatric disorder adversely affecting the quality of life of a significant number of people [1]. Schizophrenia arises from a complex and varied set of environmental and genetic factors, which has made it very difficult to come to a clear understanding of the etiology of the condition, despite intensive scientific work in the area. However, it seems that a disease arising from the interplay of genes and environment is likely to involve the super family of nuclear receptors which are known to control gene expression depending on context.

A group of 48 transcription factors play a key role in transducing extracellular (environmental, metabolic, endocrine) signals into intercellular signals, resulting in changes in expression of target genes. The nuclear receptors (NRs) are grouped into 6 functionally related sub-families (NR1—NR6) and include the estrogen and androgen receptors (NR3A1/ESR1 and NR3C4/AR), the glucocorticoid and mineralocorticoid receptors (NR3C1/GR and NR3C2/MR), the retinoid receptors (NR1B/RARs and NR2B/RXRs), the vitamin D receptor (NR1I1/VDR), the peroxisome proliferator-activated (fatty acid) receptors (NR1C/PPARs) and the orphan nuclear receptors (NR4A sub-family)[2]. A number of these genes/transcripts have been implicated in schizophrenia, including the estrogen [3, 4] and the glucocorticoid receptors [5–8], the retinoid (vitamin A) receptors [9] and the NR4A (orphan) receptors [10]. The nuclear receptors generally dimerize to form either homodimers or heterodimers with other nuclear receptors and may be activated by multiple ligands. They are therefore part of a complex network of molecules essential for development and adaptive responses in the adult.

To gain a more complete picture of alterations in nuclear receptor alterations, we have focused this study on the NR4A sub-family of nuclear receptors (NR4A1 (Nurr 77 or NGF1B), NR4A2 (Nurr1), NR4A3 (Nor1)), and their dimerization partners, the retinoid X receptors (RXRA, RXRB, RXRG) and the retinoic acid receptors (RARα, RARB, RARG).

The RAR proteins are activated by all-trans retinoic acid while the RXR proteins are activated by 9-cis retinoic acid, and other ligands such as the omega 3 unsaturated fatty acids and various synthetic compounds [11, 12]. NR4A1 and NR4A2, but not NR4A3 [13, 14], form active heterodimers with RXRA and RXRG [15, 16] and in this form can bind to the retinoid acid response elements in genomic DNA [15]. Whilst NR4A3 does not heterodimerize with the RXRs, it can interfere with the signaling from either the NR4A1-RXR or NR4A2-RXR complexes [14]. RXR dimerizes with several nuclear receptors including the retinoid receptors (RARs sub-family), the vitamin D receptor (VDR), the thyroid hormone receptors (T3Rs) and the lipid activated nuclear receptors (PPARs).

While NR4A2 has an important role in the cell body of dopaminergic neurons, the action of NR4A1 is more pronounced at target areas of the dopaminergic neurons, such as the prefrontal cortex. The NR4A1- RXR complex is suggested to function as an adaptive homeostatic regulator of dopamine neurotransmission [17]. Blockers of dopamine transmission, antipsychotics, can impact the expression of NR4A genes [18, 19] and gene ablation studies have demonstrated changes in response to antipsychotic medication in NR4A1 null mice [20, 21]. Thus, it is important to consider if the levels of antipsychotic drug levels correlate with levels of these nuclear receptor mRNAs in the brains of people with schizophrenia.

In this study, we have quantified and compared the mRNA expression of genes encoding nuclear receptors with a focus on those in the NR4A and RXR/RAR families. This study aims to determine if altered levels of the mRNA expressions in orphan nuclear receptors and retinoid receptors exist in the brains of people with schizophrenia using next generation sequencing and by real time quantitative polymerase chain reaction (RT-qPCR) in the DLPFC.
Methods

Post-mortem brain samples

Dorsal lateral prefrontal cortex (DLPFC) from thirty-seven schizophrenia/schizoaffective cases and thirty-seven controls was obtained from the New South Wales Tissue Resource Centre. Of the thirty-seven schizophrenia/schizoaffective cases, eight were on first generation antipsychotics only, twenty-two had predominantly received first generation antipsychotics, one was one second generation antipsychotics only, five had predominantly received second generation antipsychotics, and one received equal first and second generation antipsychotics. Cases were matched for sample pH, age, post-mortem interval (PMI), and RNA integrity number (RIN) (Table 1). Details of tissue characterization have been previously described [22]. All research was approved by and conducted under the guidelines of the Human Research Ethics Committee at the University of New South Wales (HREC 12435- Investigation of schizophrenia pathogenesis using post-mortem brain tissue). 300 mg of DLPFC was weighed out for total RNA extraction using TRIzol® Reagent (Life Technologies Inc., Grand Island, N.Y., U.S.A., catalogue number: 15596–018), as previously described [23]. The quantity and quality of RNA was determined using a spectrophotometer (Nanodrop ND-1000, Thermo Fisher Scientific) and Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA).

cDNA derived from total RNA from the DLPFC tissue of a cohort of 20 schizophrenia/schizoaffective cases (referred to as schizophrenia) and 20 control samples was sequenced using the ABI SOLiD platform as previously described [24]. In this study, we took the raw data generated from 19 of the schizophrenia samples and 19 control samples. We excluded one schizophrenia sample as the raw data file had been damaged and it was not possible to use it in further mapping. We also excluded one control sample who was phenotypically male but putatively XXY. We mapped the 50 nucleotide reads to the human genome (hg19) using TopHat2 (v 2.0.4) [25], which calls the Bowtie aligner (v 0.12.8) [26], allowing up to 2 bp mismatches per read (default position). HTSeq-count (Python package HTSeq, python v 2.7.3) was used to generate counts of reads uniquely mapped to known and annotated genes (freeze date October 2011) using the Ensembl annotation file GRCh37.66_chr.gtf (mode = union,~t = exon,~i = gene_name). The count table of uniquely mapped reads was then used for differential expression analysis. Differential expression was tested using the Bioconductor package, edgeR

Table 1. Control and Schizophrenia Cohort Demographics.

|                          | Control Group | Schizophrenia Group |
|--------------------------|---------------|---------------------|
| Number of Cases          | Healthy Controls = 37 | SZ = 30, SA = 7     |
| Age (years)              | 51.1 (18–78)  | 51.3 (27–75)        |
| Gender                   | F = 7, M = 30 | F = 13, M = 24      |
| Hemisphere               | L = 14, R = 23| L = 20, R = 17      |
| pH                       | 6.66 ± 0.29 (5.84–7.19) | 6.61 ± 0.30 (5.69–7.09) |
| Post-Mortem Interval (hours) | 24.8 ± 10.97 (6.5–50) | 28.8 ± 14.07 (5–72) |
| RNA Integrity Number (RIN) | 7.3 ± 0.57 (6.0–8.4) | 7.3 ± 0.58 (6.2–8.4) |
| Manner of Death          | Natural = 37  | Natural = 29, Suicide = 8 |
| Age of onset (years)     | -             | 23.7 ± 0.1          |
| Duration of Illness (years) | -            | 27.6 ± 2.3         |
| Daily Chlorpromazine Mean (mg) | -         | 692 ± 502          |
| Last Recorded Chlorpromazine Dose (mg) | -       | 542 ± 374          |

Key: SZ = schizophrenia, SA = schizoaffective; F = Female, M = Male; L = left, R = Right; ± = Standard Deviation

doi:10.1371/journal.pone.0166944.1001
and confirmed using DESeq2 (v 1.10.1) [28]. We used a generalized linear model (GLM) with batch as well as the diagnostic (schizophrenia versus control) as factors in the design matrix [29] in each of the analyses.

In carrying out this analysis, we have used read data (fastq files) obtained from RNA-Seq previously performed on the DLPFC of post-mortem brain. Tools for the analysis of RNA-Seq data have improved rapidly over recent years. Since the time when this data was first analyzed [24] commonly used analysis tools such as edgeR and DESeq have undergone important developments. They now allow covariates such as batch to be routinely incorporated in experimental analysis and provide a more sophisticated treatment of the variation in gene expression (dispersion estimation) [29, 30]. We have used these new methods in the work reported here.

In the edgeR analysis, low count transcripts were excluded and only those genes with at least 1 count per million (cpm), in at least 10 samples, were used for analysis. This filtering retained 17,483 of the original 42,358 transcripts. Normalization was performed using the trimmed mean of M values (TMM) [27]. The dispersion parameter for each gene was estimated with the Cox-Reid common dispersion method [29]. Testing for differential expression employed a negative binomial generalized linear model for each gene.

In the DESeq2 confirmatory analysis, normalization was performed using the median-of-ratios method [28]. Dispersions were estimated using a Cox-Reid adjusted profile likelihood and the Wald test for significance of GLM was used. DESeq2 invokes automatic filtering to optimize the number of genes that have an adjusted p value below the threshold (default 0.1). This resulted in the retention of 17,447 transcripts. In both workflows the Benjamini-Hochberg correction was used to correct for multiple comparisons with a false discovery rate of 0.10.

The differential expression between schizophrenia and control are distinct from those obtained in our earlier analysis [24] due to the alternative analysis streams employed. For this edgeR analysis, estimates of dispersion take into account the actual variation seen in counts for a gene across samples (tagwise dispersion) as well as the common dispersion, which is a value derived from the entire gene set. The tagwise dispersion for a gene is modulated towards the common dispersion by applying a weighting factor (prior.n). Earlier versions of edgeR set the prior.n value at 10, which moved the tagwise dispersions strongly towards the common dispersion value. This was based upon the assumption that RNA-Seq projects generally consisted of few samples and accordingly the small sample size could not alone provide a reliable estimate of dispersion. Later versions of edgeR including v 3.12.1 (used in this analysis) altered these general settings to allow greater sensitivity to the number of samples used in an experiment. The greater the number of samples, the more reliable the tagwise dispersion should be, thus reducing the modulation towards a common dispersion value. The weighting towards the common dispersion is now calculated taking account of the number of samples and groups being analysed. Under the current default settings in edgeR (v 3.12.1) the prior.df is set to 10 with a resulting prior.n of approximately 0.3 (prior.n = prior.df /residual.df). That is, for a data set of this size, with 19 individual samples, there is very little smoothing towards a common dispersion value. Instead, more weight is given to the actual variation in count numbers for a particular gene gleaned from the data for that gene. In a data set where there is a large divergence of count values for a particular gene or where there may be one or two samples with an extreme value, tagwise dispersion will make it less likely that such a gene will be called as differentially expressed. The fact that we see a reduction in differentially expressed genes using the current method is indicative of a spread of gene counts rather than a tighter clustering of values among individuals for a gene expression level.

Clustering functions available in the gplots package in the R environment (v 3.0.2) (http://www.R-project.org) [31] were used to generate heatmaps. The Metacore database was used for
ascertaining interaction partners of particular genes. The Cytoscape software platform (www.cytoscape.org) [32] was used for constructing protein interaction networks.

qPCR analysis

SuperScript® II/III First-Strand Synthesis System (Life Technologies, catalogue number: 11904-018/18080-400) was used for cDNA synthesis from 3 μg RNA. The protocol for SuperScript® II was followed by adding random hexamers, nucleoside triphosphate (dNTP), and RNase OUT to each sample. After incubating at 65˚C, tris-hydrochloride (tris-HCl), potassium chloride (KCl), magnesium chloride (MgCl₂), dithiothreitol (DTT) and SuperScript® II were added. All samples were incubated at room temperature for 10 min before heating it to 42˚C for 50 min, followed by 70˚C for 15 min. RNase H was added to all samples before incubating at 37˚C. We followed the protocol for SuperScript® III First-Strand Synthesis System according to manufacturer’s instructions.

cDNA was plated out with a seven-point serial diluted standard curve, followed by quantitative real time PCR, probing with various primers to amplify members of the nuclear receptor superfamily (Table 2). Samples were measured in triplicates on the 7900HT Fast Real-Time PCR System. The quantity means obtained from the relative standard curve method from serial dilutions of cDNA (1:3, 1:9, 1:27 etc) of our genes of interest were normalized to the geometric mean of four housekeeping genes: β-actin, ubiquitin C, glyceraldehyde-3-phosphate dehydrogenase, and TATA box binding protein (Table 2). There was no difference in the mRNA levels for housekeepers between the schizophrenia and control groups [22].

Statistical analysis of qPCR results

Normalized data was analyzed using IBM SPSS Statistics 23.0. KLF4 and RXRB were log10 transformed for normal distribution within each diagnostic group. All data were tested for correlation with age, pH, PMI and RIN. The correlations between the gene expressions with each of these factors are listed in S1 Table. ANOVA and ANCOVA were performed when appropriate. The results were analyzed for diagnostic and gender differences. We performed

| Table 2. List of Taqman genes of interest. |
|------------------------------------------|
|Gene Name| Assay ID|
|NR4A1/Nur77 Nuclear receptor subfamily 4, group A, member 1| Hs00374226_m1|
|NR4A2/Nurr1 Nuclear receptor subfamily 4, group A, member 2| Hs00428691_m1|
|NR4A3/Nor1 Nuclear receptor subfamily 4, group A, member 3| Hs00545009_g1|
|KLF4 Kruppel-like factor 4| Hs00358836_m1|
|VDR Vitamin D receptor| Hs01045840_m1|
|RARA Retinoic Acid Receptor, alpha| Hs00940446_m1|
|RARB Retinoic Acid Receptor, beta| GCAGAGCGTGTAATTACCTTGAA/GTGAGATGCTAGACTGTGCTCT|
|RARG Retinoic Acid Receptor, gamma| Hs01559234_m1|
|RXRA Retinoid X Receptor, alpha| Hs01067640_m1|
|RXRB Retinoid X Receptor, beta| Hs00232774_m1|
|RXRG Retinoid X Receptor, gamma| Hs00199455_m1|
|ACTB* Actin, beta| Hs99999903_m1|
|UBC* Ubiquitin C| Hs00824723_m1|
|GAPDH* Glyceraldehyde-3-phosphate dehydrogenase| Hs99999905_m1|
|TBP* TATA box binding protein| Hs00427620_m1|

*Housekeeper genes

doi:10.1371/journal.pone.0166944.t002
Results

Nuclear receptor family genes are expressed in three clusters

We sought to characterize nuclear receptor mRNA change in the context of the expression landscape of all nuclear receptor genes in the DLPFC. A cluster-based analysis revealed that the nuclear receptor genes expressed in the adult human prefrontal cortex fall into three main groups, highly expressed genes, moderately expressed genes and lowly expressed genes (Fig 1). Our analysis indicates that NR4A1 falls within the moderately expressed cluster and is expressed at similar abundance levels as the other members of this sub-family NR4A2 (Nurr1) and NR4A3 (Nor-1). Further, the expression levels of the NR4A genes is in a similar range to that of members of the retinoid receptors (RARs and RXRs, part of the NR1B and NR2B sub-families), and the sex steroid hormone receptors such as the estrogen and androgen receptors (ESR1 and AR). As we were interested in seeing the relative expression levels of the nuclear receptors in the DLPFC we adjusted for gene length and also clustered by gene name rather than by sample.

Nuclear receptor NR4A1 is significantly downregulated in schizophrenia

Using RNA-Seq, we analyzed gene expression in the DLPFC of 19 schizophrenia patients and compared that to 19 controls. The biological coefficient of variation (BCV) calculated using the methods available in edgeR produced a value of 0.3863 for the 19 control samples and 0.479 for the 19 schizophrenia samples. This does indicate a slightly greater degree of variability in samples from people with schizophrenia compared to samples from the controls; however it also reflects that there is also quite a bit of variability in samples from controls as well. Considerable gene expression variability was seen between individuals, which was unsurprising for human brain and patient-derived samples. This could be due to the uncontrolled factors in case-control studies (such as age at death, time of death, or gender) and also due to the heterogeneous nature of schizophrenia. Consequently, we did not see a strong distinction between the two diagnostic categories when examining global gene expression via a multidimensional scaling (MDS) plot (S1 Fig). However, a small group of genes, which had not been previously reported by us to be associated with schizophrenia, was revealed with these novel analysis parameters. The top 20 differentially expressed genes (FDR < 0.1) found using edgeR are given in Table 3. S2 Fig in the Supplementary material shows the sensitivity of the number of differentially expressed genes (found at an FDR < 0.1) to changes in prior.n from 0.3 to 2, 5 and 10. Full details of the DEGs found using these different values of prior.n are included as S2 Table.

In this analysis, the most significant differentially expressed gene was the nuclear receptor NR4A1 (Nur77), for which expression is reduced in schizophrenia (54%, p < 0.01, FDR < 0.1). The next most significant gene expression change was KLF4 (kruppel-like factor 4), which is reduced by a similar amount in schizophrenia (50% p < 0.01, FDR < 0.1). We confirmed the edgeR results using a different analysis program, DESeq2, which also found NR4A1 and KLF4 as the most significantly differentially expressed genes with decreases in schizophrenia similar to that found with edgeR (51% and 47%, respectively) (S2 Table).

To further validate these changes, quantitative PCR was used to measure the expression of these genes in the complete cohort of 74 individuals (37 schizophrenia and 37 controls). This established that both genes were significantly decreased in schizophrenia, (KLF4: F(1,69) = 8.101, p < 0.01); NR4A1: F(1,68) = 6.912, p = 0.01; Fig 2, Table 4).
qPCR analysis of the other NR4A sub-family and retinoid receptors

Using qPCR in the expanded cohort (37 schizophrenia and 37 controls), we confirmed decreased expression of NR4A1 and also found a significant decrease in NR4A2 expression in schizophrenia (NR4A2: F(1,66) = 4.655, p < 0.05) and RXRB: F(1,66) = 10.256, p < 0.01; Fig 2, Table 4). We found no significant difference for NR4A3 (F(1,68) = 1.03, p > 0.05) or the RARs
NR4A1, NR4A2, and RXRB Decreased in Schizophrenia

Correlation of gene expression among transcription factors

We performed Pearson’s correlations of the mRNA expression found by qPCR for NR4 subfamily and the retinoid receptors in our extended cohort. Correlations were performed across the combined group of controls and schizophrenia patients. We found that NR4A1 mRNA was significantly correlated with the two other closely related mRNAs NR4A2 and NR4A3. RXRG mRNA was significantly correlated with the other two RXRs (A and B). RXRB mRNA was also correlated with RARG mRNA and NR4A3 mRNA was correlated with RARA mRNA (Table 5).

Correlation between gene expression and age

We found a negative correlation between expression of the NR4A family genes and age (NR4A1: r(71) = -0.419, p = 0.0003; NR4A2: r(71) = -0.515, p = 0.000004; NR4A3: r(71) = -0.330, p = 0.005; S4 Fig). This correlation in age was found in both control and schizophrenia groups, with the correlation effect stronger in the control group (S3 Table). There was no significant correlation between age and KLF4 or any of the retinoid receptors mRNAs.

Correlation between gene expression, and chlorpromazine dosage

We found a significant negative correlation between daily chlorpromazine dosage with NR4A1 and NR4A3 (NR4A1: rho(35) = -0.594, p = 0.0002; NR4A3: rho(36) = -0.438, Table 3. Significant differentially expressed genes in schizophrenia compared to controls (FDR < 0.1) from use of edgeR.

| Gene          | Protein name                                           | log2FCa | p-valuea | FDRa |
|---------------|--------------------------------------------------------|---------|----------|------|
| NR4A1         | Nuclear receptor subfamily 4, group A member 1         | -1.13   | 1 x 10⁻⁶  | 0.019|
| KLF4          | Kruppel-like factor 4                                  | -0.99   | 6.49 x 10⁻⁶ | 0.062|
| EIF2AP4       | Eukaryotic translation initiation factor 2A pseudogene 4 | 1.08    | 2.26 x 10⁻⁵ | <0.1 |
| RTN4R         | Reticulin 4 receptor                                    | -0.69   | 2.49 x 10⁻⁵ | <0.1 |
| COL5A3        | Collagen, type V, alpha 3                              | -0.55   | 3.44 x 10⁻⁵ | <0.1 |
| ARRD3C        | Arrestin domain containing 3                           | 0.64    | 3.52 x 10⁻⁵ | <0.1 |
| ADAMTS9-AS2   | ADAMTS9 antisense RNA 2                                | 0.53    | 3.74 x 10⁻⁵ | <0.1 |
| GAREML/FAM59B | GRB2 associated, regulator of MAPK1-like               | -0.47   | 4.52 x 10⁻⁵ | <0.1 |
| MMD2          | Monocyte to macrophage differentiation-associated 2     | -0.49   | 5.26 x 10⁻⁵ | <0.1 |
| DUSP1         | Dual specificity phosphatase 1                          | -0.7    | 5.6 x 10⁻⁵  | <0.1 |
| OAS2          | 2'-5'-oligoadenylate synthetase 2, 69/71kDa            | -0.67   | 6.98 x 10⁻⁵ | <0.1 |
| ALDH1L2       | Aldehyde dehydrogenase 1 family, member L2             | 0.37    | 7.82 x 10⁻⁵ | <0.1 |
| ZNF385A       | Zinc finger protein 385A                               | -0.49   | 8.26 x 10⁻⁵ | <0.1 |
| ZNF610        | Zinc finger protein 610                                | 0.4     | 8.71 x 10⁻⁵ | <0.1 |
| PAPOLB        | Poly(A) polymerase beta (testis specific)              | 0.89    | 8.98 x 10⁻⁵ | <0.1 |
| PPP1R3B       | Protein phosphatase 1, regulatory subunit 3B            | 0.66    | 8.99 x 10⁻⁵ | <0.1 |
| SNORD116-24   | Small nucleolar RNA, C/D box 116–24                    | 0.64    | 9.02 x 10⁻⁵ | <0.1 |
| ALDH3A2       | Aldehyde dehydrogenase 3 family, member A2             | 0.3     | 9.64 x 10⁻⁵ | <0.1 |
| GABRE         | Gamma-aminobutyric acid (GABA) A receptor, epsilon     | 1.2     | 9.79 x 10⁻⁵ | <0.1 |
| GBAP1         | Glucosidase, beta, acid pseudogene 1                   | -0.57   | 1 x 10⁻⁴   | <0.1 |

aCalculated in edgeR as described in Methods

doi:10.1371/journal.pone.0166944.t003

(A, B, and G), RXRA or RXRG (all F<2.8, p>0.05, Table 4). Percentage differences in gene expression in all 10 targets examined here in the whole sample by qPCR are shown in Fig 3, and a comparison between control and schizophrenia groups of each of the gene expressions are shown in S3 Fig.
**Fig 2. Diagnostic difference of nuclear receptors and KLF4.** Graphs show the distribution of gene expression of a) KLF4 b) NR4A1 c) NR4A2 and d) RXRB normalized by the geometric mean of four housekeeper genes. Blue circles represent individual 37 control samples, and red circles represent the individual 37 schizophrenia samples, all showing mean and standard error of mean (SEM). * represents significance.

Table 4. Results from RT-qPCR analysis.

| Gene       | F-value       | p-value | df | Mean Normalized Expression for Control Group | Mean Normalized Expression for Schizophrenia Group | Percentage Change (%) |
|------------|---------------|---------|----|---------------------------------------------|---------------------------------------------------|------------------------|
| NR4A1/Nur77| F(1, 68) = 6.912 | 0.011   | 1  | 4.634 (n = 36)                              | 3.661 (n = 35)                                    | -20.99                 |
| NR4A2/Nurr1| F(1, 66) = 4.655 | 0.035   | 1  | 11.624 (n = 36)                             | 10.285 (n = 35)                                   | -11.52                 |
| NR4A3/Nor1 | F(1, 68) = 1.030 | 0.314   | 1  | 16.204 (n = 35)                             | 14.994 (n = 36)                                   | -7.47                  |
| KLF4*      | F(1, 69) = 8.101 | 0.006   | 1  | 0.864 (n = 36)                              | 0.609 (n = 35)                                    | -37.36                 |
| VDR        | F(1, 70) = 0.209 | 0.649   | 1  | 26.381 (n = 37)                             | 25.372 (n = 35)                                   | -3.83                  |
| RARA       | F(1, 66) = 0.400 | 0.529   | 1  | 2.26 (n = 35)                               | 2.324 (n = 35)                                    | 2.83                   |
| RARB       | F(1, 66) = 0.046 | 0.5     | 1  | 11.038 (n = 33)                             | 11.405 (n = 35)                                   | 3.32                   |
| RARG       | F(1, 62) = 2.824 | 0.098   | 1  | 8.457 (n = 32)                              | 7.254 (n = 34)                                    | -14.23                 |
| RXRA       | F(1, 66) = 0.744 | 0.391   | 1  | 17.36 (n = 35)                              | 19.049 (n = 34)                                   | 9.73                   |
| RXRB*      | F(1, 66) = 10.256 | 0.002  | 1  | 1.772 (n = 35)                              | 1.647 (n = 34)                                    | -24.99                 |
| RXRG       | F(1, 66) = 1.669 | 0.201   | 1  | 8.953 (n = 35)                              | 8.035 (n = 35)                                    | -10.25                 |

*Log_{10} transformed data

doi:10.1371/journal.pone.0166944.t004
p = 0.008) and no significant correlations between the last recorded chlorpromazine dosage to any of the mRNAs measured. There was a significant negative correlation between estimated lifetime chlorpromazine dosage and expression of NR4A1, NR4A2 and NR4A3 mRNAs (NR4A1: rho(35) = −0.601, p = 0.0001; NR4A2: rho(35) = −0.383, p = 0.023; NR4A3: rho(36) = −0.403, p = 0.015; Fig 4). We did not find a significant correlation with any measure of lifetime chlorpromazine and the retinoid receptor mRNAs measured (rho<0.182, p>0.05).

We also found significant negative correlations between NR4A1 and NR4A2 mRNAs with duration of illness, and a trend between NR4A3 mRNA levels and duration of illness (NR4A1: rho(35) = −0.461, p = 0.005; NR4A2: rho(35) = −0.372, p = 0.028; NR4A3: rho(36) = −0.310, p = 0.067). We did not find a significant correlation between duration of illness and any retinoid receptors mRNAs measured (rho<0.240, p>0.05).

Because there were significant correlations between the NR4A genes with age, we re-analyzed correlations between the NR4A mRNA expressions with illness duration and lifetime

| Gene   | Gene   | N  | p-value     | FDR Adjusted |
|--------|--------|----|-------------|--------------|
| NR4A1  | NR4A2  | 68 | 1.05 x 10^{-4} | 0.002        |
| NR4A1  | NR4A3  | 69 | 1.89 x 10^{-15} | 1.04 x 10^{-13} |
| NR4A3  | RARA   | 67 | 0.003       | 0.025        |
| RXRA   | RXRG   | 66 | 0.003       | 0.026        |
| RXRB   | RARG   | 63 | 4.62 x 10^{-10} | 1.27 x 10^{-8} |
| RXRB   | RXRG   | 66 | 7.9 x 10^{-4}  | 0.011        |

doi:10.1371/journal.pone.0166944.t005

doi:10.1371/journal.pone.0166944.g003
dosage in a partial correlation, factoring for age. We found NR4A1 mRNA expression remained significantly correlated with the estimated lifetime antipsychotic dosage ($r(32) = -0.401, p = 0.019$) and a trend in NR4A3 ($r(33) = -0.311, p = 0.069$).

Two-way ANCOVA of diagnosis with gender

We found there was a decrease of RXRG mRNA in females with schizophrenia ($F(1,64) = 4.97, p = 0.029$) and of RARG mRNA in females with schizophrenia ($F(1,60) = 3.942, p = 0.05$; S5 Fig). There was no significant change in all other gene targets when we analyzed by two-way ANCOVA of diagnosis and gender.

Interaction network

To investigate the biological effect of NR4A1, NR4A2 and RXRB down-regulation, we generated a network representation of the genes annotated as being transcriptionally regulated by the NR4 sub-family or RXRB (Fig 5). The downstream genes presented in Fig 5 are involved in a broad range of cellular functions, some of which are listed in S4 Table.

Generally, the annotated interactions involve transcriptional activation, although in some cases there is an inhibitory effect of the transcription factor on the target gene. We see some indication of decreased expression in genes activated by NR4A1, for instance PYGM
(phosphorylase, glycogen, muscle) (26% reduction, p<0.001, FDR<0.2), consistent with a decrease in NR4A1 activity while genes thought to be inhibited by NR4A1, such as PPARG (peroxisome proliferator-activated receptor gamma) (30% increase, p<0.005 FDR<0.4), have higher levels in schizophrenia. However, the overall picture is complicated with examples of the converse also being demonstrated. This leads us to suggest that complex mechanisms are involved in the transcriptional regulation of these genes and that down-regulation of the NR4A genes and RXRB alone may not be sufficient to induce all the expected changes in downstream gene expression.

Discussion

This study presents evidence for down-regulation of the nuclear receptors NR4A1, NR4A2, RXRB, and KLF4 mRNAs in the DLPFC in schizophrenia and evidence of reduced RARG and RXRG expression in females with schizophrenia. This study also found a negative correlation between the expression of NR4A genes and estimated levels of antipsychotic exposure. To our knowledge, this is the first study to report a correlation between clinical lifetime chlorpromazine dose and decreased expression of NR4A genes in the DLPFC. Our finding of decreased expression of NR4A1 and NR4A2 mRNA in a large cohort confirms and expands upon a
previous finding in post-mortem schizophrenia in the same area of the brain [10], whereas decrease in KLF4 mRNA overall, and RARG and RXRG mRNAs in females with schizophrenia are reported for the first time.

The therapeutic efficacy of various antipsychotic drugs depends upon antagonism of the D2 dopamine receptors [33]. Schizophrenia patients who are being treated with antipsychotic medication are subjected to constant perturbation of dopamine signaling pathways. In this study, we see a highly significant diagnostic decrease in NR4A1 mRNA in the DLPFC and a lesser decrease in NR4A2 mRNA. We also find a significant negative correlation between the estimated lifetime dose of chlorpromazine and the expression of NR4A genes in the DLPFC. This is consistent with the proposition that NR4 family genes play an important role in the frontal cortex and may be regulated via cortical dopaminergic neurotransmission.

It has previously been reported that NR4A1 and NR4A3 expression increases in the murine prefrontal cortex upon a single administration of chlorpromazine [19]. Maheux et al. studied the effect of a number of typical and atypical neuroleptics on the expression of NR4A1 and NR4A3 in different brain regions. Overall, they found that typical antipsychotics, as distinct from atypical antipsychotics, strongly induce the expression of NR4A1 and NR4A3 in striatal areas associated with control of locomotor functions with strength of induction being correlated with the affinity of the neuroleptic drug for the D2 receptor [19]. Our finding of negative correlation between the mRNA of NR4A1, NR4A2 and NR4A3 with lifetime chlorpromazine dose may appear contrary to this result. However, it also suggests that chronic administration of this medication may have a different effect to acute administration. This is in line with other studies which have reported different effects on NR4A gene expression for acute versus ongoing treatment with antipsychotics. For example, the atypical antipsychotic, Clozapine, has previously been found to affect NR4A1 expression, with acute administration resulting in an increase in NR4A1 mRNA and chronic treatment (treatment over 21 days) resulting in a decrease in NR4A1 expression [18]. Haloperidol also increased NR4A1 expression in the dorsolateral striatum on acute treatment only [18]. To date, there is little evidence that antipsychotic drugs affect RXR gene expression. We found no correlation between RXR expression and chlorpromazine medication. Langlois et al. report that haloperidol had modest effects on RXR expression in the dorsolateral portion of the striatum without any effect in other regions [34]. Although we found no correlation between retinoid gene expression and chlorpromazine it is possible that medication has an effect on other genes or proteins which interact with or affect the retinoid receptors and contribute to the gene expression changes reported here.

It has been proposed that NR4A1 and RXR work together as adaptive homeostatic regulators of dopamine function by reducing the effect of alterations in dopamine neurotransmission [17]. Given the link between NR4A genes and response to antipsychotic medication it is difficult to say whether NR4A genes are dysregulated in schizophrenia prior to commencement of antipsychotic medication. However, if dopamine signaling dysfunction is involved in the etiology of schizophrenia it is plausible that NR4A genes are vulnerable to changed expression in the development of the condition. Up or down regulation of NR4A genes is likely to have some effect on genes transcriptionally regulated by these factors. A change in NR4A can result in switching the transcriptional pathway between retinoic acid initiated (RARs) and 9-cis retinoic acid (RXRs) initiated programs [35] with potential perturbations in the dopaminergic pathways and in gene expression affected by dopamine.

Functions ascribed to NR4A1 in neuronal differentiation and neurite outgrowth [36, 37], learning and memory and immunity are all potentially relevant to schizophrenia. Notably, neurotrophic factors that promote neuronal survival and growth mediate their effect through receptors such as NR4A1 [38]. NR4A1 was first recognized through its response to nerve
growth factor (NGF), which induces neuronal differentiation and neurite outgrowth [37]. Another neurotrophin which has also been found to be reduced in schizophrenia is brain-derived neurotrophic factor [39]. A potential effect on neural plasticity is also consistent with recent work indicating that the NR4A sub-family is involved in the processes of learning and memory [40, 41].

In our analysis, we found all three NR4A receptor mRNA levels to be decreased with age. The role of NR4A receptors in brain aging is currently unknown. With human brain aging, increased DNA damage is found and since NR4A receptors may protect against DNA damage [42, 43] our finding of decreased NR4A receptors with age may contribute to loss of DNA repair in brain cells, as has been observed in damaged skin cells [44]. Another prominent event that occurs as humans age is a decrease in metabolic rate particularly in brain [45, 46] and the down regulation of NR4A synthesis may also play a role in down-regulating cellular metabolism. In support of this, an increase in metabolism is observed in muscle cells overexpressing NR4A receptors [47–49]. Thus, our findings support the hypothesis that increasing NR4A transcription or function could be a potential angle to counteract some of the effects associated with human brain aging as previously proposed [42].

The decrease in RXRB in schizophrenia is interesting as the genetic locus of RXRB (6p21.3) has been linked to schizophrenia [9]. Ablation of RXRB leads to lethality in 50% of embryos indicating an important role for this gene in early development. However, surviving embryos only display mild defects, primarily male infertility related to lipid metabolism defects in Sertoli cells [50]. Mutant mice, with ablation of RXRB-RXRG, RARB-RXRB or RARB-RXRG have shown locomotor defects and decrease of dopamine receptors DR1 and DR2 in the ventral striatum but not in the dorsal striatum [51]. There is evidence that suggests DRD2 is dysregulated in schizophrenia brains [52–54]. Krezel et al. suggest that RXRB and RXRG may be functionally redundant in locomotion control [51], which is considered a functional readout of dopamine activity in the brain.

Our finding of decreased RARG and RXRG mRNA levels in females with schizophrenia may be related to changes found in estrogen and/or estrogen receptors (ER) signaling. Indeed, direct protein interaction between the retinoid receptors and the ERs via their ligand binding domain has been documented [55, 56]. Further, retinoid receptors have been shown to be regulated by estrogen/ER [57] through an estrogen response element (ERE) on the RAR gene promoter [58–61]. RARs and ER can bind to the overlapping DNA sites [62], which may cause antagonism. However, rather than simple antagonism, there can also be cooperation between RARs and ER in the control of gene expression [63, 64]. More work needs to be done to determine the role the retinoid receptors and ER proteins in brain neuropathology and how they may be individually or reciprocally altered in schizophrenia particularly in females.

We have also found KLF4 to be differentially expressed in schizophrenia compared to controls. KLF4 is a transcription factor in the kruppel-like factor family which regulates multiple biological functions and is involved in neurogenesis, neuronal differentiation and neurite outgrowth [65]. KLF4 is regulated by RARA [66], and it can also inhibit RARA [67] in vascular smooth muscle cells in a feedback-loop fashion. KLF4 mRNA and protein expression is found to be increased in skin and breast cancer [68–71]. In skin, RARG and RXRA are found to be antagonists of KLF4 [72]. Interestingly, KLF4 inhibits cell proliferation in the brain [65] and is down-regulated in neurogenesis [73]. It has been found there may be a decreased rate of cell proliferation and decreased neurogenesis in the hippocampus in schizophrenia [74–76]. However, the role of KLF4 in differentiated cells in the cerebral cortex is not well understood.

Transcriptional regulation by the nuclear receptors is complicated by heterodimerization and their activation by multiple ligands. Furthermore, recent genome-wide studies reveal that NR binding regions are enriched for sequence motifs of other transcription factors, such as
Sp1, AP-1, and C/EBP motifs, suggesting that NRs interact with other transcription factors to regulate target gene expression [77, 78]. The NRs thus operate in a complex environment that may be tuned to provide specificity in particular tissues, cell types or environments. Quantifying and comparing the mRNA of nuclear receptors contributes to our understanding of their activity. However, a thorough investigation will also require study at the protein level. We and others have previously noted differences between protein and RNA abundance in the nuclear receptors highlighting the role of post-transcriptional regulation in these genes [6, 79]. The task of teasing out the functions of the nuclear receptors in normal and schizophrenia brains and their use as biomarkers in blood could be an area of future research. Another important research question is what cell types are expressing these nuclear receptors.

**Conclusion**

This study reports significant changes in the nuclear receptors NR4A1, NR4A2, and RXRB and KLF4 in schizophrenia and provides further evidence of a role for the nuclear receptors in the disease process. Evidence is growing in support of an important role for NR4A1 and NR4A2 in neurogenesis, learning and memory, which may be associated with the role of NR4A family genes in dopaminergic pathways. Cognitive defects and changes to dopamine signaling are well known effects of schizophrenia and of current treatment protocols. These genes also play a role in immune function which is emerging as an important focus in schizophrenia research [24, 80, 81]. More generally this work highlights the role of a subset of nuclear receptors that link environmental cues to the genetic landscape in this complex disease.

**Supporting Information**

S1 Fig. MDS plot and Venn diagram of DEGs found using edgeR and DESeq2. Multidimensional scaling (MDS) plot of all samples, SCZ samples in batch 1 (orange), Control samples in batch 1 (cyan), SCZ samples in batch 2 (red), Control samples in batch 2 (blue). (B) DEGs were identified using a glm model in both the edger and DESeq2 tools taking account of batch and SCZ, using the default settings for edgeR and DESeq2.

S2 Fig. Venn diagram of DEGs found using edgeR with different values of prior.df. The differentially expressed genes calculated using edgeR but varying the parameter prior.df, using the current default setting (prior.df = 10) and increasing this to prior.df = 70 (equivalent to prior.n = 2), and prior.df = 175 (equivalent to prior.n = 5) and prior.df = 350 (equivalent to prior.n = 10).

S3 Fig. Normalized expressions of genes by diagnosis. Overview of the normalized expressions of NR4A1, NR4A2, NR4A3, KLF4, RARA, RARB, RARG, RXRA, RXRB, and RXRG. Blue bars indicate control group and red bars indicate schizophrenia group, all showing standard error of mean (SEM). * represents significance.

S4 Fig. Correlations with age. Normalized expressions of a) NR4A1 b) NR4A2 and c) NR4A3 correlated against age.

S5 Fig. Diagnostic and Gender Differences. Two-way ANCOVA analysis of the normalized expression of diagnosis and gender of a) RARG and b) RXRG.
S1 Table. Correlations between gene expressions and correlation factors.
(XLSX)

S2 Table.  a. EdgeR DE analysis using only common dispersion. b. EdgeR DE analysis using df = 350 equating to prion.n = 10. c. EdgeR DE analysis using df = 175 equating to prion.n = 5. d. EdgeR DE analysis using df = 70 equating to prion.n = 2. e. EdgeR DE analysis using current defaults (df = 10).
(ZIP)

S3 Table. Correlation between NR4A gene expressions and Age.
(XLSX)

S4 Table. Functions associated with genes downstream of NR4A family and RXRB.
(XLSX)

Acknowledgments

MRW and SC acknowledge support from the Australian Federal Government’s Super Science and NCRIS Schemes, from the New South Wales State Government Science Leveraging Fund and Research Attraction and Acceleration Program and from the University of New South Wales.

This work was supported by Schizophrenia Research Institute (utilizing infrastructure funding from the NSW Ministry of Health and the Macquarie Group Foundation), the University of New South Wales, and Neuroscience Research Australia. CSW is a recipient of a National Health and Medical Research Council (Australia) Senior Research Fellowship (#1021970). Shan-Yuan Tsai is supported by The Cowled Postgraduate Research Scholarship in Brain Research. Tissues were received from the New South Wales Brain Tissue Resource Centre at the University of Sydney which is supported by the Schizophrenia Research Institute and National Institute of Alcohol Abuse and Alcoholism (NIH (NIAAA) R28AA012725).

Author Contributions

Conceptualization: CSW MRW.
Data curation: MRW SMC.
Formal analysis: SMC SYT.
Funding acquisition: CSW MRW.
Investigation: SMC SYT.
Methodology: CSW MRW SMC SYT.
Project administration: CSW MRW.
Resources: CSW MRW SMC SYT.
Software: SMC MRW.
Supervision: CSW MRW.
Validation: CSW MRW SMC SYT.
Visualization: SMC SYT.
Writing – original draft: SMC SYT MRW CSW.
Writing – review & editing: SMC SYT MRW CSW.

References

1. Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousono M. Quality of life in schizophrenic patients. Dialogues in clinical neuroscience. 2007; 9(2):215–26. PMID: 17726919
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83(6):835–9. PMID: 8521507
3. Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, Ward SE, Radhakrishna V, et al. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Human Molecular Genetics. 2008; 17(15):2293–309. doi: 10.1093/hmg/ddn130 PMID: 18424448
4. Wong J, Weickert CS. Transcriptional Interaction of an Estrogen Receptor Splice Variant and ErbB4 Suggests Convergence in Gene Susceptibility Pathways in Schizophrenia. Journal of Biological Chemistry. 2009; 284(28):18824–32. doi: 10.1074/jbc.M109.103243 PMID: 19439407
5. Perlman WR, Webster MJ, Kleinman JE, Weickert CS. Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biological Psychiatry. 2004; 56(11):844–52. doi: 10.1016/j.biopsych.2004.09.006 PMID: 15576061
6. Sinclair D, Tsai SY, Woon HG, Weickert CS. Abnormal Glucocorticoid Receptor mRNA and Protein Isoform Expression in the Prefrontal Cortex in Psychiatric Illness. Neuropsychopharmacology. 2011; 36(13):2698–709. doi: 10.1038/npp.2011.160 PMID: 21881570
7. Sinclair D, Webster MJ, Fullerton JM, Weickert CS. Glucocorticoid receptor mRNA and protein isoform alterations in the orbitofrontal cortex in schizophrenia and bipolar disorder. Bmc Psychiatry. 2012; 12.
8. Webster MJ, Knable MB, O’Grady J, Orthmann J, Weickert CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry. 2002; 7(9):985–94. doi: 10.1038/sj.mp.4001319 PMID: 12399952
9. Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(13):7240–4. PMID: 9636132
10. Xing GQ, Zhang L, Russell S, Post R. Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders. Schizophrenia Research. 2006; 84(1):36–56. doi: 10.1016/j.schres.2005.11.006 PMID: 16631355
11. Lefebvre P, Benomar Y, Staels B. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends in Endocrinology and Metabolism. 2010; 21(11):676–83. doi: 10.1016/j.tem.2010.06.009 PMID: 20674387
12. Lefebvre P, Martin PJ, Flajolet S, Dedieu S, Billaut X, Lefebvre B. Transcriptional activities of retinoic acid receptors. In: Litwack G, editor. Vitamins and Hormones. Vitamins and Hormones. 702005. p. 199–264.
13. Aarnisalo P, Kim CH, Lee JW, Perlmann T. Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nur77. Journal of Biological Chemistry. 2002; 277(38):35118–23. doi: 10.1074/jbc.M201707200 PMID: 12130634
14. Zetterstrom RH, Solomin L, Mitsuadis T, Olson L, Perlmann T. Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Molecular Endocrinology. 1996; 10(12):1656–66. doi: 10.1210/mend.10.12.8961274 PMID: 8961274
15. Perlmann T, Jansson L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and Nur77. Genes & Development. 1995; 9(7):769–82.
16. Sacchetti P, Dwornik H, Formstecher P, Rachez C, Lefebvre P. Requirements for heterodimerization between the orphan nuclear receptor Nur1 and retinoid X receptors. Journal of Biological Chemistry. 2002; 277(38):35088–96. doi: 10.1074/jbc.M205816200 PMID: 12122012
17. Levesque D, Rouillard C. Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends in Neurosciences. 2007; 30(1):22–30. doi: 10.1016/j.tins.2006.11.006 PMID: 17134767
18. Beaudry G, Langlois MC, Weppe I, Rouillard C, Levesque D. Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. Journal of Neurochemistry. 2000; 75(4):1694–702. PMID: 10987852
19. Maheux J, Ethier I, Rouillard C, Levesque D. Induction patterns of transcription factors of the Nur family (Nurr1, Nur77, and Nor-1) by typical and atypical antipsychotics in the mouse brain: Implication for their mechanism of action. Journal of Pharmacology and Experimental Therapeutics. 2005; 313(1):460–73. doi: 10.1124/jpet.104.080184 PMID: 15615863
20. Ethier I, Beaudry G, St-Hilaire M, Milbrandt J, Rouillard C, Levesque D. The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology. 2004; 29(2):335–46. doi: 10.1038/sj.npp.1300318 PMID: 14603264

21. Gilbert F, Morissette M, St-Hilaire M, Paquet B, Rouillard C, Di Paolo T, et al. Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover. Biological Psychiatry. 2006; 60 (6):538–47. doi: 10.1016/j.biopsych.2006.04.023 PMID: 1689530

22. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T, et al. Selection of reference gene expression in a schizophrenia brain cohort. Australian and New Zealand Journal of Psychiatry. 2010; 44 (1):59–U21. doi: 10.3109/00048670903393662 PMID: 20073568

23. Kozlovsky N, Shannon-Weickert C, Tomaskovic-Crook E, Kleinman JE, Belmaker RH, Agam G. Reduced GSK-3 beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. Journal of Neural Transmission. 2004; 111(12):1583–92. doi: 10.1007/s00702-004-0166-3 PMID: 15565492

24. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, et al. Selection of reference gene expression in a schizophrenia brain cohort. Australian and New Zealand Journal of Psychiatry. 2010; 44 (1):59–U21. doi: 10.3109/00048670903393662 PMID: 20073568

25. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biology. 2013; 14(4).

26. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biology. 2009; 10(3).

27. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26(1):139–40. doi: 10.1093/bioinformatics/btp616 PMID: 19910308

28. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biology. 2010; 11(10).

29. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifacto RNA-Seq experiments with respect to biological variation. Nucleic Acids Research. 2012; 40(10):4288–97. doi: 10.1093/nar/gks042 PMID: 22878627

30. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology. 2014; 15(12).

31. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. gplots: Various R programming tools for plotting data. R package version 2.12.1. Available online at: http://CRAN.R-project.org/package=gplots; 2013.

32. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Research. 2003; 13 (11):2498–504. doi: 10.1101/gr.1239303 PMID: 14597658

33. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: A review on efficacy and side effects. Current Medicinal Chemistry. 2004; 11(3):343–58. PMID: 14965236

34. Langlois MC, Beaudry G, Zekki H, Rouillard C, Levesque D. Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain. Neuroscience. 2001; 106(1):117–28. PMID: 11564422

35. Levesque D, Rouillard C. Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends in neurosciences. 2007; 30(1):22–30. Epub 2006/12/01. doi: 10.1016/j.tins.2006.11.006 PMID: 17134767

36. Lee YW, Stachowiak EK, Birkaya B, Terranova C, Capacchietti M, Claus P, et al. NGF-induced cell differentiation and gene activation is mediated by integrative nuclear FGFR1 signaling (INFS). Plos one. 2013; 8(7):e68931. Epub 2013/07/23. PubMed Central PMCID: PMC3707895. doi: 10.1371/journal.pone.0068931 PMID: 23874817

37. Milbrandt J. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. Neuron. 1988; 1(3):183–8. PMID: 3272167

38. Lee YW, Stachowiak EK, Birkaya B, Terranova C, Capacchietti M, Claus P, et al. NGF-Induced Cell Differentiation and Gene Activation Is Mediated by Integrative Nuclear FGFR1 Signaling (INFS). Plos One. 2013; 8(7).

39. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Molecular Psychiatry. 2003; 8 (6):592–610. doi: 10.1038/sj.mp.4001308 PMID: 12851636

40. Hawk JD, Abel T. The role of NR4A transcription factors in memory formation. Brain Research Bulletin. 2011; 85(1–2):21–9. doi: 10.1016/j.brainresbull.2011.02.001 PMID: 21316423
41. Hawk JD, Bookout AL, Poplawski SG, Bridi M, Rao AJ, Sulewski ME, et al. NR4A nuclear receptors support memory enhancement by histone deacetylase inhibitors. Journal of Clinical Investigation. 2012; 122(10):3593–602. doi: 10.1172/JCI64145 PMID: 22996661

42. Paillasse MR, de Medina P. The NR4A nuclear receptors as potential targets for anti-aging interventions. Medical Hypotheses. 2015; 84(2):135–40. doi: 10.1016/j.mehy.2014.12.003 PMID: 25543265

43. Pols TWH, De Vries CJM. A shining future for NR4A nuclear receptors in DNA repair. Pigment Cell & Melanoma Research. 2008; 21(3):342–3.

44. Smith AG, Luk N, Newton RA, Roberts DW, Sturm RA, Muscat GEO. Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. Journal of Biological Chemistry. 2008; 283(18):12564–70. doi: 10.1074/jbc.M800480200 PMID: 18292087

45. Kuzawa CW, Chugani HT, Grossman LI, Lipovich L, Muscat O, Hof PR, et al. Metabolic costs and evolutionary implications of human brain development. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(36):13010–5. doi: 10.1073/pnas.1320399111 PMID: 25157149

46. Peters R. Ageing and the brain. Postgraduate Medical Journal. 2006; 82(964):84–8. doi: 10.1136/pgmj.2005.036665 PMID: 16461469

47. Chao LC, Wroblewski K, Ilyayeva OR, Stevens RD, Bain J, Meyer GA, et al. Skeletal muscle Nur77 expression enhances oxidative metabolism and substrate utilization. Journal of Lipid Research. 2012; 53(12):2610–9. doi: 10.1194/jlr.M029355 PMID: 23028113

48. Pearen MA, Eriksson NA, Fitzsimmons RL, Goode JM, Martel N, Andrikopoulos S, et al. The Nuclear Receptor, Nor-1, Markedly Increases Type II Oxidative Muscle Fibers and Resistance to Fatigue. Molecular Endocrinology. 2012; 26(3):372–84. doi: 10.1210/me.2011-1274 PMID: 22282471

49. Pearen MA, Goode JM, Fitzsimmons RL, Eriksson NA, Thomas GP, Cowin GJ, et al. Transgenic Muscle-Specific Nor-1 Expression Regulates Multiple Pathways That Effect Adiposity, Metabolism, and Endurance. Molecular Endocrinology. 2013; 27(11):1897–917. doi: 10.1210/me.2013-1205 PMID: 24065705

50. Kastner P, Mark M, Leid M, Gansmuller A, Chinn W, Grondona JM, et al. Abnormal spermatogenesis in RXR beta mutant mice. Genes & Development. 1996; 10(1):80–92.

51. Krezel W, Ghyselinck N, Samad TA, Dupe V, Kastner P, Borrelli E, et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science. 1998; 279(5352):863–7. PMID: 9452386

52. Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R, et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain. 2009; 132:417–25. doi: 10.1093/brain/awn248 PMID: 18829695

53. Cohen O, Weickert T, Hess J, Paish L, McCoy S, Rothmond D, et al. A splicing-regulatory polymorphism in DRD2 disrupts ZRANB2 binding, impairs cognitive functioning and increases risk for schizophrenia in six Han Chinese samples. Molecular psychiatry. 2015.

54. Kuzawa CW, Chugani HT, Grossman LI, Lipovich L, Muscat O, Hof PR, et al. Melanocortin signaling in retinoid receptor mutant mice. Science. 1998; 279(5352):863–7. PMID: 9452386

55. Kuzawa CW, Chugani HT, Grossman LI, Lipovich L, Muscat O, Hof PR, et al. Melanocortin signalin g in retinoid receptor mutant mice. Science. 1998; 279(5352):863–7. PMID: 9452386

56. Kaalund SS, Newburn EN, Ye T, Tao R, Li C, Deep-Soboslay A, et al. Contrasting changes in DRD1 and DRD2 splicing variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain. Molecular Psychiatry. 2014; 19(12):1258–66. doi: 10.1038/mp.2013.165 PMID: 24322206

57. Song MR, Lee SK, Seo YW, Choi HS, Lee JW, Lee MO. Differential modulation of transcriptional activity of oestrogen receptors by direct protein-protein interactions with retinoid receptors. Biochemical Journal. 1998; 336:711–7. PMID: 981885

58. Lee SK, Choi HS, Song MR, Lee MO, Lee JW. Estrogen receptor, a common interaction partner for a subset of nuclear receptors. Molecular Endocrinology. 1998; 12(8):1184–92. doi: 10.1210/mend.12.8.0146 PMID: 9717844

59. Lu M, Mira-y-Lopez R, Nakajo S, Nakaya K, Jing YK. Expression of estrogen receptor alpha, retinoid acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells. Oncogene. 2005; 24(27):4362–9. doi: 10.1038/sj.onc.1208661 PMID: 15870697

60. Lagniariere J, Deblois G, Giguere V. Functional genomics identifies a mechanism for estrogen activation of the retinoid acid receptor alpha 1 gene in breast cancer cells. Molecular Endocrinology. 2005; 19(6):1584–92. doi: 10.1210/me.2005-0040 PMID: 15831516

61. Segars JH, Marks MS, Hirschfeld S, Driggers PH, Martinez E, Grippo JF, et al. Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways. Molecular and Cellular Biology. 1993; 13(4):2258–68. PMID: 8384307

62. Nunez SB, Medin JA, Keller H, Wang K, Ozato K, Wahil W, et al. Retinoid X receptor beta and peroxisome proliferator-activated receptor activate an estrogen response element. In: Bardin CW, editor. Recent Progress in Hormone Research, Vol 50: Proceedings of the 1993 Laurentian Hormone Conference. Recent Progress in Hormone Research. 50:1995. p. 409–16.
61. Klinge CM, Bodenner DL, Desai D, Niles RM, Traish AM. Binding of type II nuclear receptors and estrogen receptor to full and half-site estrogen response elements in vitro. Nucleic Acids Research. 1997; 25(10):1903–12. PMID: 9115356
62. Hua S, Kittle R, White KP. Genomic Antagonism between Retinoic Acid and Estrogen Signaling in Breast Cancer. Cell. 2009; 137(7):1259–71. doi: 10.1016/j.cel.2009.04.043 PMID: 19563758
63. Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes & Development. 2010; 24(2):171–82.
64. Rousseau C, Pettersson F, Couture MC, Paquin A, Galipeau J, Mader S, et al. The N-terminal of the estrogen receptor (ER alpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 2003; 86(1):1–14. PMID: 12943740
65. Qin S, Zhang C-L. Role of Kruppel-Like Factor 4 in Neurogenesis and Radial Neuronal Migration in the Developing Cerebral Cortex. Molecular and Cellular Biology. 2012; 32(21):4297–305. doi: 10.1128/MCB.00838-12 PMID: 22337869
66. Shi J-h, Zheng B, Chen S, Ma G-y, Wen J-k. Retinoic Acid Receptor alpha Mediates All-trans-retinoic Acid-induced Klf4 Gene Expression by Regulating Klf4 Promoter Activity in Vascular Smooth Muscle Cells. Journal of Biological Chemistry. 2012; 287(14):10799–811. doi: 10.1074/jbc.M111.321836 PMID: 22337869
67. Zheng B, Han M, Bernier M, Zhang X-h, Meng F, Miao S-b, et al. Klf4-positive cells block the proliferation—differentiation switch and initiate squamous epithelial dysplasia. Oncogene. 2005; 24(9):1491–500. doi: 10.1038/sj.onc.1208307 PMID: 15674344
68. Huang CC, Liu ZL, Li XN, Bailey SK, Foster KW, et al. KLF4 and PCNA identify stages of tumor initiation in a conditional model of cutaneous squamous epithelial neoplasia. Cancer Biology & Therapy. 2005; 4(12):1401–8.
69. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 2011; 30(18):2161–72. doi: 10.1038/onc.2010.591 PMID: 21242971
70. Jiang W, Deng WT, Bailey SK, Nail CD, Frost AR, Brouillette WJ, et al. Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid. Cancer Biology & Therapy. 2009; 8(3):285–94.
71. Qin S, Liu M, Niu W, Zhang C-L. Dysregulation of Kruppel-like factor 4 during brain development leads to hydrocephalus in mice. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(22):21117–21. doi: 10.1073/pnas.1112351108 PMID: 22160720
72. Allen KM, Fung SJ, Weickert CS. Cell proliferation is reduced in the hippocampus in schizophrenia. Australian and New Zealand Journal of Psychiatry. 2016; 50(5):473–80. doi: 10.1177/0004867415589795 PMID: 26113745
73. Kempermann G, Krebs J, Fabel K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Current Opinion in Psychiatry. 2008; 21(3):290–5. doi: 10.1097/YCO.0b013e3282f3c75 PMID: 18382230
74. Reif A, Frizzen S, Finger M, Strobel A, Lauer M, Schmitt A, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Molecular Psychiatry. 2006; 11(5):514–22. doi: 10.1038/sj.mp.4001791 PMID: 16415915
75. Biddie SC, John S, Hager GL. Genome-wide mechanisms of nuclear receptor action. Trends in Endocrinology and Metabolism. 2010; 21(1):3–9. doi: 10.1016/j.tem.2009.08.006 PMID: 19800253
76. Jagannathan V, Robinson-Rechavi M. The challenge of modeling nuclear receptor regulatory networks in mammalian cells. Molecular and Cellular Endocrinology. 2011; 334(1–2):91–7. doi: 10.1016/j.mce.2010.06.012 PMID: 20605894
77. Krekel W, Astner P, Shamir P. Differential expression of retinoid receptors in the adult mouse central nervous system. Neuroscience. 1999; 89(4):1291–300. PMID: 10362315
78. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Weickert CS. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Translational Psychiatry. 2014; 4.
81. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016; 530(7589):177+. doi: 10.1038/nature16549 PMID: 26814963